SARS-CoV-IN-3 是一种有效的 SARS-CoV 复制抑制剂。在 Vero 细胞中，SARS-CoV-IN-3 抗冠状病毒，EC50 为 3.6 μM。SARS-CoV-IN-3 抑制 P. falciparum 3D7 和 W2 株，IC50 分别为 11.7 和 20.4 nM； IC90 分别为 29.19 和 56 nM。在 MT-4 细胞中，SARS-CoV-IN-3 降低 HIV-1 诱导的细胞病变，EC50 为 10 μM。具有抗疟和抗病毒活性。
| Cas No. | 888958-27-8 |
| Canonical SMILES | CCN(CCO)CC12=C3[Fe+2]1456789([C-]%10C6=C7C8=C9%10)[C-]2(CNC%11=CC=NC%12=C%11C=CC(Cl)=C%12)C4=C53 |
| 分子式 | C25H20ClFeN3O |
| 分子量 | 469.74 |
| 溶解度 | DMSO: 7.81 mg/mL (16.63 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells[1]. [1]. Biot C, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006 May 4;49(9):2845-9. |
